Repurposed Effect of (177)Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium (177)Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal...

Descripción completa

Detalles Bibliográficos
Autores principales: Elajami, Mohamad K., Burton, Lorena P., Bahmad, Hisham F., Chaaya, Gerard, Schwartz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599960/
https://www.ncbi.nlm.nih.gov/pubmed/36290871
http://dx.doi.org/10.3390/curroncol29100594
Descripción
Sumario:Mantle cell lymphoma (MCL) is an uncommon subcategory of non-Hodgkin lymphoma (NHL). Pathogenesis primarily includes overexpression of CCND1 and SOX11 along with other molecular aberrations. Lutetium (177)Lu-DOTATATE is a radiolabeled somatostatin analogue used for the treatment of gastrointestinal neuroendocrine tumors. There are no clinical data supporting the use of Lutetium (177)Lu-DOTATATE in the treatment of lymphoma. We describe the case of an 84-year-old man with a history of MCL and carcinoid tumor of the lung. Following progression of the carcinoid malignancy, the patient was treated with Lutetium (177)Lu-DOTATATE. After treatment, there was an overall improvement of the patient’s MCL that was demonstrated by stable lymphadenopathy on serial CT scans and down-trend of the absolute lymphocyte count. Therefore, we hypothesize that (177)Lu-DOTATATE might have a role and can be repurposed for treating MCL.

Ejemplares similares